Dual Listed Biotech Begins to Prepare POC Preclinical Study for Diabetes & Obesity Dual Gene Therapy Program

Obesity and diabetes have become a problem for developed world countries. To address the global rise of these issues, this company is pursuing a dual-gene therapy strategy using proprietary bionanotechnological approaches. The rational design of tissue-targeted bioresponsive gene delivery systems (completed) will now be accompanied by gene- and protein-silencing in animal models of obesity and diabetes.

PreveCeutical Medical Inc.  (CSE: PREV) (OTCQB: PRVCF) announced in a press release today that it has begun preparations to accelerate the completion of its preclinical dual gene therapy program using their developed and in vitro validated Smart-siRNA sequences, which when paired with their proprietary and patented bioresponsive lipid-nanoparticulate delivery systems effectively target the PTPN1 gene.

The firm has received direct interest in its diabetes and obesity dual gene therapy program from a world-leading pharmaceutical company established in the diabetes and obesity therapeutic space. Explicit interest in the gene target has been expressed while also requesting the completion of gene-protein silencing efficacy and safety evaluation studies in rodent disease models, employing the firm’s lead Smart-siRNA bio-responsive carrier systems. 

Canadian shares closed Friday trade at $0.025.

Copyright © 2023 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com’s content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

]]>